Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
17 enrolled 15 charts
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Phase 1 Terminated
272 enrolled
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Phase 1 Terminated
189 enrolled
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
Phase 1/2 Terminated
2 enrolled 7 charts
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Phase 1 Terminated
21 enrolled
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Phase 1 Terminated
24 enrolled 21 charts
VZCLLPI0146
Phase 2 Terminated
5 enrolled 10 charts
Javelin DLBCL
Phase 3 Terminated
29 enrolled 24 charts
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Phase 2 Terminated
11 enrolled 12 charts
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Phase 1 Terminated
2 enrolled
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
Phase 2 Terminated
23 enrolled
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
Phase 2 Terminated
9 enrolled 2 charts